SCHEMBL4715660

SCHEMBL4715660

CCOC(=O)c1cc2c(ccc[n+]2[O-])n1Cc1ccccc1C#N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
KDM4E B2RXH2 5/20 0.48
TDP1 Q9NUW8 4/20 0.48
TSHR P16473 4/20 0.48
RECQL P46063 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NOD2 Q9HC29 1/20 0.43
NOD1 Q9Y239 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
POLB P06746 1/20 0.39
ATM Q13315 1/20 0.39
F10 P00742 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713887 0.82 MAPT (0.57) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4717230 0.78 MAPT (0.47) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4714613 0.78 NOD2 (0.51) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4717021 0.76 MAPT (0.50) MAPTKDM4ETDP1TSHRALDH1A1
SCHEMBL4713175 0.75 MAPT (0.46) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4715544 0.75 NOD2 (0.48) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4789540 0.74 MAPT (0.49) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL4714912 0.74 MAPT (0.50) MAPTKDM4ETDP1TSHRRECQL
SCHEMBL6223161 0.69 CNR2 (0.63) MAPTKDM4ETDP1TSHRALDH1A1
SCHEMBL6170560 0.67 HTT (0.54) MAPTHSD17B10MAPK1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPT 1831/4885KDM4E 2030/4885TDP1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.